EIDX News and Press, Eidos Therapeutics Inc. From 10/09/20

WILMINGTON, Del., Oct. 09, 2020 (GLOBE NEWSWIRE) -- Andrews & Springer LLC , a boutique securities class action law firm focused on representing shareholders nationwide, is investigating potential breach of fiduciary duty claims against the Board of Directors of Eidos Therapeut...

NEW YORK, NY / ACCESSWIRE / October 8, 2020 / Labaton Sucharow, a nationally ranked shareholder rights firm, is investigating potential securities violations and breach of fiduciary duty claims against clinical-stage biotech company Eidos Therapeutics. (NASDAQ:EIDX). If you currently own ...

Eidos Therapeutics ([[EIDX]] +3.3%) downgraded to neutral by Citi analyst Joel Baetty, and the PT revised to $73.26, down from $80.The analyst believes BridgeBio's (BBIO) offer to acquire the remaining outstanding shares of Eidos for $73.26 per share is 'fairly likely to materialize.'Also, he...

Labaton Sucharow, a nationally ranked shareholder rights firm, is investigating potential securities violations and breach of fiduciary duty claims against clinical-stage biotech company Eidos Therapeutics. (NASDAQ: EIDX). If you currently own shares of Eidos and want to receive add...

Gainers: Greenpro Capital (GRNQ) +85%.MyoKardia (MYOK) +58%.Westwater Resources (WWR) +53%.Eidos Therapeutics (EIDX) +40%.Scully Royalty (SRL) +34%.Enlivex Therapeutics (ENLV) +28%.Humanigen (HGEN) +24%.Corvus Pharmaceuticals (CRVS) +22%.Piedmont Lithium (PLL) +22%.Pulse Biosciences (PLS...

Shares of Eidos Therapeutics (NASDAQ: EIDX) were skyrocketing 41.1% higher as of 11:50 a.m. EDT on Monday. The huge gain came after BridgeBio Pharma (NASDAQ: BBIO) announced plans to acquire Eidos. BridgeBio already owns a major stake in Eidos. It's now seeking to buy th...

Gainers: MyoKardia (MYOK) +58%, Eidos Therapeutics (EIDX) +41%, Enlivex Therapeutics (ENLV) +25%, Humanigen (HGEN) +28%, Corvus Pharmaceuticals (CRVS) +26%.Losers: Xtant Medical Holdings (XTNT) -15%, Curis (CRIS) -7%, Immunome (...

MyoKardia (MYOK) +59% as Bristol to acquire the company for $225/Share.Kosmos Energy (KOS) +50% as company closed a Gulf of Mexico facility with Beal Bank USA and Trafigura Trading LLC.Enlivex Therapeutics (ENLV) +49%.Corvus Pharmaceuticals (CRVS) +38% on co-foun...

BridgeBio Pharma (BBIO) and Eidos Therapeutics (EIDX) have entered into an agreement under which BridgeBio has agreed to acquire all of the outstanding common stock of Eidos it does not already own, representing ~36.3% of outstanding shares.Eidos stockholders will have the right to receive, e...

SAN FRANCISCO, Aug. 07, 2020 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Nasdaq: EIDX), a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need in diseases caused by transthyretin (TTR) amyloidosis (ATTR), today announced that it has added two new...